NOVAVAX - Ein möglicher Impfstoffentwickler?

Novavax, Inc.
US-Kürzel: NVAX
WKN: 898527
Totalverlust möglich. Dies stellt keine Kauf- oder Verkaufsempfehlung dar, sondern spiegelt nur meine Meinung wieder. Jeder handelt auf eigenes Risiko.

Novavax, Inc. entwickelt Impfstoffe für infektiöse Krankheiten. Novavax verachtfachte sich bei der Vogelgrippe-Epidemie. Seit dem die Schweinegrippe "die Runde" macht, explodierte erneut das Volumen. Zu den fundamentals kann ich keinerlei Bewertung abgeben.

 

einmal einen Hotstock (ausser Arafura) und gleich ne Doppel-ID in meinem Thread.

12 Wochen?

...An analyst said that technology could cut the production time down to 12 weeks, and that Novavax had seen similar stock boosts during the bird flu outbreak in 2006...

http://www.bizjournals.com/washington/stories/2009/04/27/daily5.html

Die Schweinegrippe verbreitet sich (leider) schneller als gedacht. Das dürfte Novavax weiter beflügeln.

Hier einige Infos zu der Aktie:
Plenty of Good Reasons to Buy NVAX Now 28-Apr-09 08:16 pm
1. There was a good chance of receiving U.S. Gov't. contract in 2009 to complete development of vaccine against pandemic avian flu even before swine flu arose.
2. There is a good chance of receiving gov't. swine flu vaccine contract/s if swine flu continues.
3. Partnership with GE Healthcare--Highly likely to sign up one or more regional deals (starting this qtr.) with one or more foreign governments for manufacturing pandemic flu vaccine and seasonal flu vaccine in those countries (see NVAX website)
4. There have already been two successful human clinical trials of NVAX's pandemic flu vaccine and one successful human clinical trial of its seasonal flu vaccine. NVAX pandemic flu vaccine works better than any other in existence and is completely safe because VLPs do not contain actual virus or adjuvants.
5. Quickest and most cost efficient vaccine manaufacturing capability of any vaccine company. Although current manufacturing capacity (pilot plant in Maryland) is limited, that problem can be solved by GE and/or gov't.throwing money at it.
6. RSV vaccine candidate produced excellent preclinical results and is available for partnering--could easily become a $1 billion product by itself.
7.Shingles vaccine candidate in preclinical stage-same story as 6.
8.Recent joint venture with Cadila will provide NVAX an opportunity to sell its vaccine products in India (1.3 billion pop.) and to develop other vaccines at reduced cost to NVAX. Cadila deal also generated $10 million of new capital.
9.Cleveland Clinic named NVAX Top 10 new bio company likely to revolutionize vaccine industry.
10.Swine flu epidemic will increase attention and opportunities available to NVAX, making vaccine deals with foreign governments more likely
11. About 50% of company was owned by insiders and smart money before swine flu arose--these folks were not selling at .80 and are not selling out now at $3.18. These investors are looking for and will hold for $20 and up.
12.Stock was way oversold at .80--so there's still plenty of room to make tons of money over the next few years notwithstanding the run up of the past 3 days. NVAX could easily be worth $20/share or more in a couple of years even if swine flu fizzles out.
13. And if it doesn't fizzle out--- if this is the big pandemic---then just hang on and enjoy the ride to $50 plus.

Quelle: yahooboard

 

und zwar denke ich das diese Schweinegrippe zur Zeit kleingeredet wird.Man hat ja schon genug Probleme in der Welt da käme eine Pandemie wirklich zu einem falschen Zeitpunkt.

Ich glaube wir erleben noch nen kräftigen Schub nach Norden bei allen Aktien die etwas in diesem Sektor anzubieten haben.  

At the biotech company Novavax, researchers are testing the use of virus-like particles (VLP), instead of the virus itself, to stimulate a flu immune response. Using this method, a vaccine for the 2009 H1N1 virus could be in production in 10 to 12 weeks, rather than the usual four to six months. "We have made vaccines against multiple flu strains and tested them in humans and gotten relevant and robust immune responses, which checks off the major boxes that the technology works against flu," says Rahul Singhvi, president and CEO of Novavax.

Diese Technologie könnt im Ernstfall helfen. Hier der vollständige Bericht:
http://www.time.com/time/health/article/...94625,00.html?iid=tsmodule

 

http://www.novavax.com/download/File/NVAX_Conver_April_09_FO.pdf  

http://www.deraktionaer.de/xist4c/web/...us_id_261__dId_10086009_.htm

Novavax will den Auftrag

Auf einen solchen Auftrag zur Entwicklung eines Impfstoffes hatten wohl auch viele Anleger spekuliert, die bei Novavax zugriffen und das Papier der kleinen US-Biotech-Schmiede seit Ende letzter Woche um mehr als 200 Prozent in die Höhe katapultieren. Zu dem Höhenflug dürfte auch eine aktuelle Empfehlung aus dem Hause Rodman & Renshaw beigetragen haben, die das Papier mit einem Kursziel von vier Dollar zum Kauf empfehlen. Das wäre selbst nach dem jüngsten Höhenflug ein weiteres Kurspotenzial von über 130 Prozent.

Dass die Aktie von Novavax bei der zunehmenden Hysterie um die Schweinepest weiter steigt, ist nicht auszuschließen. Aber es gibt noch ein weiteres Kaufargument: Für den Jahresverlauf hat das Unternehmen die Ergebnisse zweier klinischer Studien angekündigt. Im dritten Quartal werden Resultate aus einer klinischen Phase-II-Studie mit einem neuen Grippemittel erwartet. Weitere Daten stehen für das vierte Quartal an, bei dem der Wirkstoff an älteren Patienten getestet wurde. Wer kurzfristig von der "Schweinepest-Hysterie" profitieren will, legt sich jetzt einige Stücke ins Depot und sichert etwaige Gewinne durch stetige Anpassung des Stoppkurses ab. Wer eher auf gute Daten spekulieren will, sollte warten, bis die Panik aus dem Markt gewichen ist und die Aktie korrigiert hat.

...bin gespannt was nachher passiert, gestern "drüben" Schluss im Tageshoch...!
WEITER SO!  

WOW - Weiter so!!!!
bitte anschnallen...!
;-)  

Novavax kündigt Kooperation mit National Institute of Health bei Schweinegrippe-Impfstoff an, Aktie hebt ab

16:26 04.06.09

Rockville (aktiencheck.de AG) - Der US-Biotechnologiekonzern Novavax Inc. (Profil) gab am Donnerstag eine Kooperation mit der Division of Microbiology and Infectious Diseases (DMID) des National Institute of Allergy and Infectious Diseases (NIAID) sowie dem National Institute of Health (NIH) in Zusammenhang mit der Entwicklung eines Impfstoffkandidaten für den als Schweinegrippeerreger bekannten Virus Influenza A (H1N1) bekannt.

Demnach habe der Biotechnologiekonzern bereits drei Woche nach Ausbruch des Schweinegrippevirus aus einer Probe einen Stamm von virusähnlichen Partikeln des Influenza-Stamms extrahiert, der im Vergleich zum Original-Schweinegrippevirus jedoch nicht infektiös wirkt. Auf Basis dieser Entwicklung will man gemeinsam mit den oben genannten Institutionen an einem Schweinegrippe-Impfstoff für Menschen und Tiere arbeiten, teilte der Konzern weiter mit.

Die Aktie von Novavax notiert aktuell mit einem Plus von 49,73 Prozent bei 2,80 Dollar. (04.06.2009/ac/n/a)  

http://www.n-tv.de/panorama/Meldungen/...demie-aus-article349097.html  

Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009



ROCKVILLE, Md., June 18 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) a clinical-stage vaccine company, announced today that Dr. Rahul Singhvi, President and Chief Executive Officer, will be presenting at the Phacilitate Vaccine Forum Barcelona 2009 conference on June 22 and June 23, 2009 at The Fira Palace, Barcelona, Spain. Dr. Singhvi is participating in the Panel Session 'How are VLP based vaccines helping to shape the manufacturing processes of the future?' andwill also be speaking to the Case Study: Highlighting the clinical milestones to date:What progress is being made with respect to immune response in healthy adults?Presentations will be available on www.novavax.com after the event.


ABOUT NOVAVAX

Novavax, Inc. (Nasdaq: NVAX) is a clinical stage biotechnology company, creating novel vaccines, including H1N1, to address a broad range of infectious diseases worldwide using advanced proprietary virus-like particle (VLP) technology. The Company produces these VLP based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at www.novavax.com and in the Company's various filings with the Securities and Exchange Commission.


Forward-Looking Statement

Statements herein relating to future development results and performance, conditions or strategies and other matters, including expectations regarding product and clinical developments, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act. Novavax cautions that these forward-looking statements are subject to numerous assumptions, risks and uncertainties, which change over time. Factors that may cause actual results to differ materially from the results discussed in the forward-looking statements or historical experience include risks relating to the early stage of Novavax's product candidates under development; current results may not be predictive of future pandemic results, results of our seasonal influenza vaccine or any other vaccine that we may develop; further testing is required before regulatory approval can be applied for and the FDA may not approve a vaccine even if further trial results are similar to those disclosed previously by the company; uncertainties relating to clinical trials , including possible delays in initiating or completing the trials and safety and efficacy results ; dependence on the efforts of third parties; competition for clinical resources and patient enrollment from drug candidates in development by other companies with greater resources and visibility; and risks that we may lack the financial resources and access to capital to fund our operations including further clinical trials. Further information on the factors and risks that could affect Novavax's business, financial conditions and results of operations, is contained in Novavax's filings with the U.S. Securities and Exchange Commission, which are available at http://www.sec.gov . These forward-looking statements speak only as of the date of this press release, and Novavax assumes no duty to update forward-looking statements.


SOURCE Novavax, Inc.  

so sieht es die Umwelt-Journalistin Jane Burgermeister

Journalist Files Charges against WHO and UN for Bioterrorism and Intent to Commit Mass Murder
http://www.naturalnews.com/026503_pandemic_swine_flu_bioterrorism.html

"In her charges, Burgermeister presents evidence of acts of bioterrorism that is in violation of U.S. law by a group operating within the U.S. under the direction of international bankers who control the Federal Reserve, as well as WHO, UN and NATO. This bioterrorism is for the purpose of carrying out a mass genocide against the U.S. population by use of a genetically engineered flu pandemic virus with the intent of causing death. This group has annexed high government offices in the U.S.

Specifically, evidence is presented that the defendants, Barack Obama, President of the U.S, David Nabarro, UN System Coordinator for Influenza, Margaret Chan, Director-General of WHO, Kathleen Sibelius, Secretary of Department of Health and Human Services, Janet Napolitano, Secretary of Department of Homeland Security, David de Rotschild, banker, David Rockefeller, banker, George Soros, banker, Werner Faymann, Chancellor of Austria, and Alois Stoger, Austrian Health Minister, among others, are part of this international corporate criminal syndicate which has developed, produced, stockpiled and employed biological weapons to eliminate the population of the U.S. and other countries for financial and political gain."  

Spanish Government Selects Novavax's VLP Technology for Comprehensive Flu Vaccine Solution in Spain

http://ih.advfn.com/...77719&article=38441743&symbol=N%5ENVAX  

Two More Promising Attacks on Flu and Swine Flu (VICL, NVAX)
June 30, 2009
Vical Inc. (NASDAQ: VICL) showed promising swine flu test data in its animal model today and was one of the top rising stocks. A pact from Novavax, Inc. (NASDAQ: NVAX) with the government of Spain and ROVI Pharmaceuticals sent its shares even higher on a percentage basis.

Vical Incorporated (NASDAQ: VICL) said tests in its vaccine against A/H1N1 pandemic influenza, the swine flu, produced robust immune responses that were “well above the accepted protection threshold in 100% of vaccinated mice and rabbits” after a standard two-dose vaccine regimen. The company said that at least 75% of vaccinated animals achieved or exceeded the protection threshold after a single dose of vaccine. Vical went so far as saying that it is ready to advance directly to large-scale cGMP manufacturing of the vaccine for human clinical trials, subject to securing external funding for this program.

Novavax, Inc. (NASDAQ: NVAX) signed a deal with Spain’s health ministry and ROVI Pharma, a specialty drug maker in Spain, to license its genetically engineered technology to produce pandemic and seasonal flu vaccines and build that country’s first vaccine-making plant.

While exact terms are outstanding, this could easily bring in tens of millions of dollars in future royalty and milestone payments if and after the vaccines are approved and marketed. The target here is to get both pandemic flu vaccines and seasonal flu vaccines by 2012.

ROVI has committed to make a $3 million equity investment in Novavax at $2.74, a 10% premium to yesterday’s close. The Spanish government is forming a foundation and will invest in a 60 million facility and a non-profit foundation will be formed will be formed and initially funded with a 25 million euro credit line from the Spanish government.

This was a huge boom for both companies today. Vical Inc. (NASDAQ: VICL) rose over 22% to $2.70, on over 8 million shares. Novavax, Inc. (NASDAQ: NVAX) shares closed up 31% at $3.28, on over 32 million shares. As far as how high that volume is, that is about 14-times average on Vical and nearly 8-times average volume on Novavax.

Jon C. Ogg

Tags: NVAX, VICL  

 

http://www.cnbc.com/id/31826227/site/14081545  

 

 

heute umgesetzt, gehandelt.  Mal schauen ob das eine Eintagsfliege war.
Die Indiktoren sind teils gut am Anschlag...  

 

Super Meldung, für mich der ideale Übernahmekandidat für Novartis!

NOVAVAX Achieves Pandemic H1N1 Influenza Production Milestone
cGMP quality material produced in 11 weeks from strain availability
Press Release
Source: Novavax, Inc.
On Wednesday August 5, 2009, 7:30 am EDT
      Buzz up! 0 Print
Companies:Novavax, Inc.
ROCKVILLE, Md., Aug. 5 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX - News) announced today it has manufactured a virus-like particle (VLP) vaccine candidate against the H1N1 pandemic influenza virus under current good-manufacturing practices (cGMP) at its new vaccine manufacturing facility in Rockville, MD. This milestone was accomplished in only 11 weeks after receiving the gene sequence for the H1N1 strain from the U.S. Centers for Disease Control. The Company was able to reach this manufacturing goal by employing proprietary, novel production technology which is not dependent on growing influenza virus in eggs. Chicken eggs are used to produce almost all of the world's influenza vaccine supply. In addition, Novavax has produced essential reagents for measuring vaccine potency. The Company also has plans to produce additional batches of the pandemic H1N1 VLP vaccine to support human clinical studies and stands ready to assist with additional public health needs in the US as well as foreign countries.

Related Quotes
Symbol Price Change
NVAX 4.63 0.00


{"s" : "nvax","k" : "c10,l10,p20,t10","o" : "","j" : ""} A detailed timeline describing the process from gene sequence to cGMP manufacturing is available on the Novavax website (www.Novavax.com).

Mr. Jim Robinson, Vice President of Manufacturing and Quality Operations at Novavax, commented, "Demonstration of our ability to construct and produce GMP-quality influenza vaccine within 12 weeks under real pandemic conditions is an important and successful test of our VLP technology. With further scale up, recombinant influenza VLP vaccine technology has the potential to expand vaccine surge capacity and significantly reduce the timeline for vaccine release. We are proud of our staff who worked tirelessly to achieve this important milestone while working concurrently to produce materials for a clinical study in the elderly population with our Seasonal Flu vaccine."

"The accomplishments announced today further validate our strategy to create a rapid, in-border influenza vaccine solution for governments around the world by addressing gaps in currently available vaccine technologies," added Dr. Rahul Singhvi, President and CEO of Novavax, Inc.

Novavax, Inc has successfully completed a Phase I/IIa clinical study with a candidate H5N1 influenza VLP vaccine and is currently in Phase II trials with a VLP based seasonal flu vaccine candidate. The Company plans to initiate a Phase II study with its Seasonal Flu vaccine candidate in the elderly population during Q4, 2009.

About Novavax

Novavax, Inc. is a clinical-stage biotechnology company creating novel vaccines to address a broad range of infectious diseases worldwide, including H1N1, using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP-based, potent, recombinant vaccines utilizing new and efficient manufacturing approaches. Additional information about Novavax is available at w